Mitomycin extravasation injury: A case series

[1]  N. E. El Saghir,et al.  Overview, prevention and management of chemotherapy extravasation. , 2016, World journal of clinical oncology.

[2]  O. Abbas,et al.  Syringometaplasia: variants and underlying mechanisms , 2016, International journal of dermatology.

[3]  D. Schrijvers.  Extravasation: a dreaded complication of chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Furue,et al.  Delayed Tissue Necrosis Associated with Mitomycin‐C Administration , 2000, The Journal of dermatology.

[5]  JalpaKailasbhai Patel,et al.  Distant and Delayed Mitomycin C Extravasation , 1999, Pharmacotherapy.

[6]  O. Garrone,et al.  Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Alberts,et al.  Case report: topical DMSO for mitomycin-C-induced skin ulceration. , 1991, Oncology nursing forum.

[8]  R. Rentschler,et al.  Pyridoxine: A potential local antidote for mitomycin‐C extravasation , 1988, Journal of surgical oncology.

[9]  H. Tagami,et al.  Delayed tissue necrosis due to mitomycin C. , 1987, Acta Dermato-Venereologica.

[10]  H. Stoll,et al.  Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and alpha-tocopherole. , 1987, European journal of cancer & clinical oncology.

[11]  R. Dorr,et al.  Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Reville,et al.  Extensive tissue ulceration due to apparent sensitivity reactions to mitomycin. , 1985, Cancer treatment reports.